Genmab — Juni 2019

[Bulder]

Eatwell på sidste CC: We're looking for $3 billion as you know for 2019. And we expect that growth to be roughly split evenly between the 2 regions, $500 million U.S., $500 million rest of world to a total growth of $1 billion or 50%. That means with a higher U.S. starting point for the U.S., we're looking for a 42% growth U.S., 62% rest of world.
Now in terms of the growth that we anticipate for the U.S., $500 million.

[Bulder]

I would anticipate that may -- or frontline multiple myeloma would contribute approximately half to that. So somewhere in the $200 million to $250 million coming from the frontline indication. As Jan said, we expect approval imminently, and we expect there's going to be quite demand for that product. And we would expect the sales to pick up quite quickly.

[StockBull]

1185

[JKY_VH]

Aktien stryger til vejrs skriver Børsen, tjah https://borsen.dk/nyheder/virksomheder/artikel/1/383802/ny_godkendelse_til_genmab_fordobler_markedspotentiale_i_usa_aktien_stryger_til_vejrs.html?utm_source=forside&utm_campaign=nyhed_01

[JKY_VH]

men når "lykkeridderne" er væk, kan det da være, at de får ret.

[JKY_VH]

ja vi kører tilsyneladende på diesel i dag:-)

[transalp]

Sejtræk er der ikk noget galt ved..:)

[JKY_VH]

bestemt ikke, den kommer helt nede fra:-)

[JKY_VH]

Vi cruiser gennem 1200

[Bulder]

Mens vi keder os, mere Eatwell: One other final point on that, remember that dosing for DARZALEX is that you start off with weekly dosing then go to bi-weekly and then on to your once every 4 weeks. So it does mean you do get that sort of hockey stick on the start of the sales where you get that nice, extra sales per patient certainly for the first 6 months compared to the ongoing period. So we still remain confident around our $3 billion for the year.

[StockBull]

Ja de bliver nok først i Oktober vi kan se om det bliver over de 3 mia

[AaBforever]

Hu..hej..hvor det går..:-D

[AaBforever]

oppe med 5,5%

[JKY_VH]

jep, er der nogen der har set om der er kommentarer fra Novod, Bowers eller Løntoft?

[bikube]

Huhej hvor det går - vi nærmer os ugens højeste kurs.

[Teller]

som nævn igår, 1250-1280 idag, opjustering til November. Denne godkendelse sætter alt andet lige en kæmpe pæl gennem tvivlernes argumenter.

[Teller]

herfra skal vi skal op i niveauet fra 2017

[iboge]

Lad os nu først se nogle stigende salgstal inden vi sætter kursen alt for højt.

[E_L]

Saad Usmani @szusmani
Our group @LevineCancer will be using it for standard risk TI-NDMM pts.
https://twitter.com/szusmani/status/1144359670427136000

[Teller]

nu er det jo Biotek, så lad os nu se hvad der sker på kursen her til eftermiddag.